Disease Drugs Pharmacogenetics Research 
The Open Targets Blog
MARCH 20, 2024
We have implemented this analysis for eight sources of target-disease association evidence where there is enough information available to make an assessment. The assessment is tailored to each dataset; this is detailed in our target-disease evidence documentation. million evidence. DOI: 10.1016/j.ccell.2023.12.016
The Open Targets Blog
NOVEMBER 30, 2023
Target prioritisation A major new feature of this release is the Target Prioritisation view, which provides an assessment of target-specific properties of interest when evaluating the suitability of a target for a drug discovery programme. Target prioritisation view for Crohn's Disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 5, 2022
DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery. . RA: How can bioprinting be used to shorten drug discovery timelines? . This allows researchers to identify the best individual drugs to treat the disease. .
Drug Discovery World
OCTOBER 25, 2023
DDW Editor Reece Armstrong speaks to Dr Darrell Green , Lecturer in RNA Biology Biomedical Research Centre Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development.
The Pharma Data
OCTOBER 27, 2020
Food and Drug Administration (FDA). SAN DIEGO , Oct. Clinical laboratories can process thousands of samples each day for less than $10 per sample running the assay on a single MassARRAY instrument, making it one of the highest throughput SARS-CoV-2 tests available under the Emergency Use Authorization program.
Expert insights. Personalized for you.
85 
Let's personalize your content